Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 411

1.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.

Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F.

Ann Hematol. 2018 Jun 27. doi: 10.1007/s00277-018-3400-z. [Epub ahead of print]

PMID:
29951912
2.

Towards home-based treatment for acute promyelocytic leukaemia, with caution.

Lo-Coco F, Cicconi L.

Lancet Oncol. 2018 Jun 5. pii: S1470-2045(18)30355-3. doi: 10.1016/S1470-2045(18)30355-3. [Epub ahead of print] No abstract available.

PMID:
29884592
3.

Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL.

Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, van der Werff Ten Bosch J, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Foà R, Locatelli F, Kaspers GJL.

Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528. [Epub ahead of print]

PMID:
29789356
4.

Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers.

Efficace F, Cottone F, Sparano F, Lo-Coco F.

Cancer. 2018 Jul 15;124(14):3066-3067. doi: 10.1002/cncr.31521. Epub 2018 Apr 30. No abstract available.

PMID:
29710399
5.

Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes.

Martínez-Losada C, Serrano-López J, Serrano-López J, Noguera NI, Garza E, Piredda L, Lavorgna S, Irno Consalvo MA, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jérez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibañez M, Sempere A, Sanz MÁ, Lo Coco F, Sánchez-García J.

Haematologica. 2018 Apr 5. pii: haematol.2018.188433. doi: 10.3324/haematol.2018.188433. [Epub ahead of print] No abstract available.

6.

The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation.

Faraoni I, Aloisio F, De Gabrieli A, Consalvo MI, Lavorgna S, Voso MT, Lo-Coco F, Graziani G.

Cancer Lett. 2018 Jun 1;423:127-138. doi: 10.1016/j.canlet.2018.03.008. Epub 2018 Mar 8.

PMID:
29526802
7.

Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.

Buccisano F, Maurillo L, Del Principe MI, Di Veroli A, De Bellis E, Biagi A, Zizzari A, Rossi V, Rapisarda V, Amadori S, Voso MT, Lo-Coco F, Arcese W, Venditti A.

Expert Rev Hematol. 2018 Apr;11(4):307-313. doi: 10.1080/17474086.2018.1447378. Epub 2018 Mar 7.

PMID:
29495904
8.

Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia.

Gurnari C, Panetta P, Fabiani E, Nardone AM, Postorivo D, Falconi G, Franceschini L, Rizzo M, Rapisarda VM, De Bellis E, Lo-Coco F, Voso MT.

Mol Clin Oncol. 2018 Mar;8(3):463-465. doi: 10.3892/mco.2017.1543. Epub 2017 Dec 29.

9.

Longitudinal detection of DNMT3AR882H transcripts in patients with acute myeloid leukemia.

Ottone T, Alfonso V, Iaccarino L, Hasan SK, Mancini M, Divona M, Lavorgna S, Cicconi L, Panetta P, Maurillo L, Del Principe MI, Irno Consalvo M, Franceschini L, Angelini DF, Battistini L, Guerrera G, De Bardi M, Fabiani E, Falconi G, Arcese W, Amadori S, Buccisano F, Venditti A, Voso MT, Lo-Coco F.

Am J Hematol. 2018 May;93(5):E120-E123. doi: 10.1002/ajh.25061. Epub 2018 Feb 24. No abstract available.

PMID:
29417611
10.

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Franca-Neto PL, Coelho-Silva JL, de Deus Wagatsuma VM, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Chiattone CS, Fagundes EM, Chauffaille ML, Schrier SL, Tallman MS, Ribeiro RC, Grimwade D, Ganser A, Löwenberg B, Lo-Coco F, Sanz MA, Berliner N, Rego EM.

Blood Adv. 2017 Sep 15;1(21):1807-1814. doi: 10.1182/bloodadvances.2017005926. eCollection 2017 Sep 26.

11.

Progress and criticalities in the management of acute promyelocytic leukemia.

Lo-Coco F, Cicconi L, Voso MT.

Oncotarget. 2017 Nov 12;8(59):99221-99222. doi: 10.18632/oncotarget.22385. eCollection 2017 Nov 21. No abstract available.

12.

The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia.

Fabiani E, Falconi G, Noguera NI, Saulle E, Cicconi L, Divona M, Banella C, Picardi A, Cerio AM, Boe L, Sanchez M, Pelosi E, Testa U, Lo-Coco F, Voso MT.

Oncotarget. 2017 Sep 20;8(48):84074-84085. doi: 10.18632/oncotarget.21101. eCollection 2017 Oct 13.

13.

Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation.

Mastrangelo D, Pelosi E, Castelli G, Lo-Coco F, Testa U.

Blood Cells Mol Dis. 2018 Mar;69:57-64. doi: 10.1016/j.bcmd.2017.09.005. Epub 2017 Sep 21. Review.

PMID:
28954710
14.

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Iaccarino L, Ottone T, Hasan SK, Divona M, Cicconi L, Lavorgna S, Alfonso V, Basso G, Barragán E, Bocchia M, Rego EM, Grimwade D, Voso MT, Lo-Coco F.

Leuk Lymphoma. 2018 May;59(5):1268-1270. doi: 10.1080/10428194.2017.1369067. Epub 2017 Aug 24. No abstract available.

PMID:
28838264
15.

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.

Masciarelli S, Capuano E, Ottone T, Divona M, De Panfilis S, Banella C, Noguera NI, Picardi A, Fontemaggi G, Blandino G, Lo-Coco F, Fazi F.

Leukemia. 2018 Feb;32(2):285-294. doi: 10.1038/leu.2017.231. Epub 2017 Aug 4.

16.

Treatment of Low-Blast Count AML using Hypomethylating Agents.

De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Review.

17.

Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?

Efficace F, Gaidano G, Lo-Coco F.

Blood. 2017 Aug 17;130(7):859-866. doi: 10.1182/blood-2017-03-737403. Epub 2017 Jul 10. Review.

PMID:
28694324
18.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.

N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.

19.

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.

Abla O, Ribeiro RC, Testi AM, Montesinos P, Creutzig U, Sung L, Di Giuseppe G, Stephens D, Feusner JH, Powell BL, Hasle H, Kaspers GJL, Dalla-Pozza L, Lassaletta A, Tallman MS, Locatelli F, Reinhardt D, Lo-Coco F, Hitzler J, Sanz MA.

Ann Hematol. 2017 Sep;96(9):1449-1456. doi: 10.1007/s00277-017-3042-6. Epub 2017 Jun 8.

PMID:
28597167
20.

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.

Noguera NI, Pelosi E, Angelini DF, Piredda ML, Guerrera G, Piras E, Battistini L, Massai L, Berardi A, Catalano G, Cicconi L, Castelli G, D'Angiò A, Pasquini L, Graziani G, Fioritoni G, Voso MT, Mastrangelo D, Testa U, Lo-Coco F.

Oncotarget. 2017 May 16;8(20):32550-32565. doi: 10.18632/oncotarget.15925.

21.

Clonal evolution in therapy-related neoplasms.

Fabiani E, Falconi G, Fianchi L, Criscuolo M, Ottone T, Cicconi L, Hohaus S, Sica S, Postorino M, Neri A, Lionetti M, Leone G, Lo-Coco F, Voso MT.

Oncotarget. 2017 Feb 14;8(7):12031-12040. doi: 10.18632/oncotarget.14509.

22.

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.

Lange AP, Lima AS, Lucena-Araujo AR, Jácomo RH, Melo RA, Bittencourt RI, Pasquini R, Pagnano K, Fagundes EM, Chauffaille ML, Chiattone CS, Sanz MA, Lo-Coco F, Grimwade D, Rego EM.

Br J Haematol. 2018 Mar;180(6):915-918. doi: 10.1111/bjh.14490. Epub 2016 Dec 26. No abstract available.

PMID:
28025822
23.

PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.

Ronchini C, Brozzi A, Riva L, Luzi L, Gruszka AM, Melloni GEM, Scanziani E, Dharmalingam G, Mutarelli M, Belcastro V, Lavorgna S, Rossi V, Spinelli O, Biondi A, Rambaldi A, Lo-Coco F, di Bernardo D, Pelicci PG.

Leukemia. 2017 Sep;31(9):1975-1986. doi: 10.1038/leu.2016.386. Epub 2016 Dec 27.

PMID:
28025581
24.

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.

Forghieri F, Bigliardi S, Quadrelli C, Morselli M, Potenza L, Paolini A, Colaci E, Barozzi P, Zucchini P, Riva G, Vallerini D, Lagreca I, Marasca R, Narni F, Venditti A, Martelli MP, Falini B, Lo Coco F, Amadori S, Luppi M.

Clin Case Rep. 2016 Oct 24;4(12):1138-1146. eCollection 2016 Dec.

25.

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, Cudillo L, De Angelis G, Sarlo C, Cefalo M, Ditto C, Di Veroli A, Mariotti B, Nasso D, De Bellis E, Del Poeta G, Voso MT, Sconocchia G, Lo Coco F, Arcese W, Amadori S, Venditti A.

Bone Marrow Transplant. 2017 Mar;52(3):473-475. doi: 10.1038/bmt.2016.308. Epub 2016 Dec 12. No abstract available.

PMID:
27941782
26.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

27.

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, De Bellis E, Di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso MT, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052. eCollection 2016. Review.

28.

Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.

Piredda ML, Catalano G, Ciardi C, Divona M, Cicconi L, Panetta P, Curzi P, Garza E, Martínez-Losada C, Postorino M, Lo-Coco F, Noguera NI.

Ann Hematol. 2017 Jan;96(1):155-157. doi: 10.1007/s00277-016-2843-3. Epub 2016 Oct 13. No abstract available.

PMID:
27734129
29.

Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol.

Testi AM, Moleti ML, Canichella M, Mohamed S, Diverio D, de Propris MS, Locatelli F, Lo Coco F, Foà R.

Leuk Lymphoma. 2017 Apr;58(4):999-1001. doi: 10.1080/10428194.2016.1222377. Epub 2016 Sep 23. No abstract available.

PMID:
27658340
30.

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.

Noguera NI, Piredda ML, Taulli R, Catalano G, Angelini G, Gaur G, Nervi C, Voso MT, Lunardi A, Pandolfi PP, Lo-Coco F.

Oncotarget. 2016 Oct 11;7(41):66386-66397. doi: 10.18632/oncotarget.11964.

31.

Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations.

Guarnerio J, Bezzi M, Jeong JC, Paffenholz SV, Berry K, Naldini MM, Lo-Coco F, Tay Y, Beck AH, Pandolfi PP.

Cell. 2016 Aug 11;166(4):1055-1056. doi: 10.1016/j.cell.2016.07.035. No abstract available.

32.

Panobinostat for the treatment of acute myelogenous leukemia.

Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, Iovino L, Benedetti E, Lo-Coco F, Galimberti S.

Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8. Review.

PMID:
27485472
33.

PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL.

di Masi A, Cilli D, Berardinelli F, Talarico A, Pallavicini I, Pennisi R, Leone S, Antoccia A, Noguera NI, Lo-Coco F, Ascenzi P, Minucci S, Nervi C.

Cell Death Dis. 2016 Jul 28;7:e2308. doi: 10.1038/cddis.2016.115.

34.

A case of SRSF2 mutation in chronic lymphocytic leukemia.

Garza E, Del Poeta G, Martínez-Losada C, Catalano G, Borgia L, Piredda ML, Fabiani E, Gattei V, Lo-Coco F, Noguera NI.

Leuk Res Rep. 2016 Jun 23;6:11-4. doi: 10.1016/j.lrr.2016.03.001. eCollection 2016.

35.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.

36.

PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.

Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco F.

Leukemia. 2016 Oct;30(10):1987-1992. doi: 10.1038/leu.2016.122. Epub 2016 May 2.

PMID:
27133819
37.

Current management of newly diagnosed acute promyelocytic leukemia.

Cicconi L, Lo-Coco F.

Ann Oncol. 2016 Aug;27(8):1474-81. doi: 10.1093/annonc/mdw171. Epub 2016 Apr 15. Review.

PMID:
27084953
38.

PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response.

Saulle E, Petronelli A, Pelosi E, Coppotelli E, Pasquini L, Ilari R, Lo-Coco F, Testa U.

J Hematol Oncol. 2016 Apr 7;9:33. doi: 10.1186/s13045-016-0262-5.

39.

Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations.

Guarnerio J, Bezzi M, Jeong JC, Paffenholz SV, Berry K, Naldini MM, Lo-Coco F, Tay Y, Beck AH, Pandolfi PP.

Cell. 2016 Apr 7;165(2):289-302. doi: 10.1016/j.cell.2016.03.020. Epub 2016 Mar 31. Erratum in: Cell. 2016 Aug 11;166(4):1055-1056.

40.

Targeted Therapy Alone for Acute Promyelocytic Leukemia.

Lo-Coco F, Di Donato L; GIMEMA, Schlenk RF; German–Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia.

N Engl J Med. 2016 Mar 24;374(12):1197-8. doi: 10.1056/NEJMc1513710. No abstract available.

41.

Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.

Testa U, Lo-Coco F.

Ann Hematol. 2016 Apr;95(5):673-80. doi: 10.1007/s00277-016-2622-1. Epub 2016 Feb 26. Review.

PMID:
26920716
42.

Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.

Iaccarino L, Ottone T, Divona M, Cicconi L, Cairoli R, Voso MT, Lo-Coco F.

Br J Haematol. 2016 Mar;172(6):909-13. doi: 10.1111/bjh.13910. Epub 2016 Jan 5. Erratum in: Br J Haematol. 2016 Jul;174(2):335.

PMID:
26728337
43.

Current standard treatment of adult acute promyelocytic leukaemia.

Lo-Coco F, Cicconi L, Breccia M.

Br J Haematol. 2016 Mar;172(6):841-54. doi: 10.1111/bjh.13890. Epub 2015 Dec 21. Review.

PMID:
26687281
44.

Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.

Efficace F, Mandelli F, Platzbecker U, Cottone F, Lo Coco F.

Blood. 2015 Nov 26;126(22):2523-4. doi: 10.1182/blood-2015-07-658922. Epub 2015 Oct 9. No abstract available.

45.

High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

Lucena-Araujo AR, Kim HT, Thomé C, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Glória AB, Chauffaille Mde L, Athayde M, Chiattone CS, Mito I, Bendlin R, Souza C, Bortolheiro C, Coelho-Silva JL, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Blood. 2015 Nov 12;126(20):2302-6. doi: 10.1182/blood-2015-01-623330. Epub 2015 Oct 1.

46.

Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.

Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M, Mueller U, Tang B.

Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):771-7. doi: 10.1016/j.clml.2015.07.634. Epub 2015 Aug 5.

47.

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.

Voso MT, Lo-Coco F, Fianchi L.

Curr Opin Oncol. 2015 Nov;27(6):532-9. doi: 10.1097/CCO.0000000000000231. Review.

PMID:
26352541
48.

Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.

Kruse M, Wildner R, Barnes G, Martin M, Mueller U, Lo-Coco F, Pathak A.

PLoS One. 2015 Aug 12;10(8):e0134587. doi: 10.1371/journal.pone.0134587. eCollection 2015.

49.

Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines.

Mastrangelo D, Massai L, Lo Coco F, Noguera NI, Borgia L, Fioritoni G, Berardi A, Iacone A, Muscettola M, Pelosi E, Castelli G, Testa U, Di Pisa F, Grasso G.

Ann Hematol. 2015 Nov;94(11):1807-16. doi: 10.1007/s00277-015-2464-2. Epub 2015 Aug 12.

PMID:
26264692
50.

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.

Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE.

Br J Haematol. 2015 Nov;171(4):471-7. doi: 10.1111/bjh.13607. Epub 2015 Jul 24.

Supplemental Content

Loading ...
Support Center